Impact of Time-to-Treatment Initiation and First Inter-Cycle Delay in Patients with Hodgkin Lymphoma
Open Access
- 10 June 2025
- journal article
- research article
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (12) , 4085
Abstract
Background: Delays in treatments are frequent in real-world lymphoma management. This study evaluates the impact of diagnosis-to-treatment intervals (DTIs) and first inter-cycle delay (IcD) on outcomes in patients with Hodgkin lymphoma (HL) receiving ABVD chemotherapy. Methods: We retrospectively analyzed 137 patients with classical HL treated with ABVD at a single institution between 2015 and 2022. Results: The median age was 34 years (range: 18–73), and 62% were male. The median DTI was 14 days, with 24.1% of patients experiencing a delay of >7 days between the first and second chemotherapy cycles. The most frequent reason for delay was neutropenia, observed in 69% of delayed cases. Neither DTI nor IcD was significantly associated with PFS or OS. Multivariate analysis identified elevated beta-2 microglobulin as an independent predictor of both inferior PFS and OS. Conclusions: This is the first study to evaluate both DTI and first IcD as independent prognostic factors in HL. Modest delays in treatment initiation or early cycle administration did not negatively affect survival. Timely but flexible scheduling of ABVD may be appropriate in HL. Prospective studies are warranted in the era of novel therapeutic agents.Keywords
This publication has 29 references indexed in Scilit:
- Fear of Cancer Recurrence and Associated Factors in Lymphoma Survivors and Their Family Caregivers: A Cross‐Sectional StudyCancer Medicine, 2025
- Immune checkpoint blockade and CAR T-cell therapy in T-cell/histiocyte-rich large B-cell lymphoma: Challenges and opportunitiesHeliyon, 2024
- The impact of inter-cycle treatment delays on overall survival in patients with advanced-stage ovarian cancerThe Oncologist, 2024
- The impact of inter-cycle treatment delays on 5-year all-cause mortality in early-stage breast cancer: A retrospective cohort studyEuropean Journal of Cancer, 2024
- Immunotherapy in hematologic malignancies: achievements, challenges and future prospectsSignal Transduction and Targeted Therapy, 2023
- Development and validation of a risk score (Delay-7) to predict the occurrence of a treatment delay following cycle 1 chemotherapyESMO Open, 2022
- Importance of diagnosis-to-treatment interval in newly diagnosed patients with diffuse large B-cell lymphomaScientific Reports, 2021
- Mortality due to cancer treatment delay: systematic review and meta-analysisBMJ, 2020
- The impact of time from diagnosis to treatment in diffuse large B-cell lymphomaLeukemia & Lymphoma, 2018
- Predictors of delay in diagnosis and treatment in diffuse large B‐cell lymphoma and impact on survivalBritish Journal of Haematology, 2014